Agoracom: Small Cap Investment - Zenith Epigenetics - Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

in response to

Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

KOO-KOO2

posted on Feb 28, 2022 09:29AM

And there is an additional 6 Clinical Trials ongoing involving ZEN-3694. And the market price for ZHCLF (Zenith Capital Corp, a sister company to Resverlogix Corp., ticker symbol TSE: RVX and OTC: RVXCF) is presently sitting at $010 US. This is unbelievable, to say the least.

Zenith's Oncology pipeline.

https://clinicaltrials.gov/ct2/show/NCT04840589

https://clinicaltrials.gov/ct2/show/NCT04986423#contacts

https://clinicaltrials.gov/ct2/show/NCT03901469

https://clinicaltrials.gov/ct2/show/NCT04471974

https://clinicaltrials.gov/ct2/show/NCT03051659

https://clinicaltrials.gov/ct2/show/NCT05111561

And there may be others.

Koo

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply